Select the account you'd like to open
Trade CFDs on over 10,000+ shares, FX pairs, commodities, indices and treasuries
Share trading account
Invest in Australian shares, a range of ETFs, warrants, mFunds
Read more about IPOs and placements with CMC Markets Invest
Novogen is an Australian biotechnology company listed on both the Australian Securities Exchange (NRT) and NASDAQ (NVGN).
Novogen owns two proprietary drug technology platforms that are first-in class and which the Company believes will be the foundation that will enable us to grow into a major global bio-pharmaceutical force.
The corporate goal is the development of a suite of drugs that will destroy tumours before they have a chance to recur and become un-treatable based on a combination of its two proprietary technology platforms:
The proceeds will be used for general working capital and to fund the company’s R&D programs. However, the primary use of the funds is to underwrite the transition of the Company’s lead product, Cantrixil into the clinic.
|InMINIMUM AMOUNT:||$5 million|
|MAXIMUM AMOUNT:||$10 million|
|NO. OF SHARES:||up to 80 million new shares and 1 attached option per share|
|ISSUE PRICE:||$0.11 per share|
|OFFER OPEN:||Monday, 3 November 2014|
|OFFER CLOSE:||3pm, Tuesday 11 November 2014
(Issuer reserves the right to close the offer earlier)
|MINIMUM ALLOCATION:||$5000 available for on market bidders|
|TECHNICAL LEAD MANAGER:||CMC Markets Invest|
|ACCESS:||All brokers via ASX Bookbuild via ASX code NRTXBB|
Click here for investor presentation.
Offer is open to Sophisticated investor clients only.
CMC Markets Invest
GPO Box 5351
Sydney NSW 2001
Once this is in place, call our Dealing Desk on 1300 136 323 to secure your interest.
*only applicable if you have not previously participated in ASX BB.
** sophisticated investor certifications are valid for 6 months. This will not be required if it has previously been provided to CMC Markets and is still valid.
CMC Markets does not endorse any material, recommendations, commentary, analysis, trade suggestions or external research discussed or distributed by or on behalf of any external Company or provider and does not accept any responsibility for any claims, liability, loss or damage arising out of or in connection with any external Company or provider. The information contained in this website does not constitute personal financial advice. You should seek your own independent legal, taxation or investment advice as appropriate before making an investment decision.
Anyone who wants to acquire shares in Novogen will need to carefully consider the offer and complete the CMC Markets Bookbuild Agreement and Sophisticated Certification available from our website before placing a trade.
For more information on ASX Bookbuilds please visit the ASX fact sheet at: www.asx.com.au/documents/professionals/ASX_Bookbuild_Brochure.pdf